Literature DB >> 16125637

Secular trends in outcomes for Fanconi anemia patients who receive transplants: implications for future studies.

Philip S Rosenberg1, Blanche P Alter, Gerard Socié, Eliane Gluckman.   

Abstract

Transplantation protocols for patients with Fanconi anemia are being modified continuously. However, it is unclear how outcomes have changed over time. We determined historical adverse event rates from long-term follow-up of 117 Fanconi anemia patients in the Hôpital Saint Louis transplant cohort, who received low-dose cyclophosphamide- and irradiation-based conditioning, in combination with other modalities, between 1976 and October 2002. In high-risk patients with mismatched donors, the peritransplantation mortality rate during 0 to 6 months declined significantly over time (P = .003), from 28%/month (95% confidence interval [CI], 9%-87%/month) during 1985 to 1989 to 3.3%/month (95% CI, 0.8%-13.3%/month) during 2000 to October 2002. The corresponding proportion of patients who developed severe acute graft-versus-host disease also declined significantly over time (P = .003). In low-risk patients with matched sibling donors, the peritransplantation mortality rate was consistently low, 1.4%/month (95% CI, 0.3%-5.3%/month), during 1990 to October 2002. Sample sizes to detect 2-fold reductions from rates and risks observed since the mid-1990s are larger than recently reported case series. To demonstrate further advances in survival, transplant centers may need to coordinate their protocols and engage in multicenter collaborative studies.

Entities:  

Mesh:

Year:  2005        PMID: 16125637     DOI: 10.1016/j.bbmt.2005.05.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

Review 1.  Neonatal manifestations of inherited bone marrow failure syndromes.

Authors:  Payal P Khincha; Sharon A Savage
Journal:  Semin Fetal Neonatal Med       Date:  2015-12-24       Impact factor: 3.926

2.  Fanconi Anemia with MDS RAEB-2 Rapidly Progressing to AML in a 5-Year-Old Boy.

Authors:  H Rama; Devika Gupta; Tathagata Chatterjee; Srishti Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-01       Impact factor: 0.900

3.  Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?

Authors:  Parinda A Mehta; Chie Emoto; Tsuyoshi Fukuda; Brian Seyboth; Ashley Teusink-Cross; Stella M Davies; Jamie Wilhelm; Kirsten Fuller; Alexander A Vinks; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-18       Impact factor: 5.742

4.  Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Authors:  Parinda A Mehta; Stella M Davies; Thomas Leemhuis; Kasiani Myers; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Richard J O'Reilly; David A Williams; Leslie Lehmann; Eva Guinan; David Margolis; K Scott Baker; Adam Lane; Farid Boulad
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

5.  HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.

Authors:  Carmem M Bonfim; Carlos R de Medeiros; Marco A Bitencourt; José Zanis-Neto; Vaneuza A M Funke; Daniela C Setubal; Jefferson Ruiz; Jean E Sanders; Mary E D Flowers; Hans-Peter Kiem; Rainer Storb; Ricardo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2007-10-18       Impact factor: 5.742

Review 6.  Fanconi anemia.

Authors:  Allison M Green; Gary M Kupfer
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

7.  Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Authors:  Antonio M Risitano; Serena Marotta; Rita Calzone; Francesco Grimaldi; Adriana Zatterale
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

8.  Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.

Authors:  P Anur; D N Friedman; C Sklar; K Oeffinger; M Castiel; J Kearney; B Singh; S E Prockop; N A Kernan; A Scaradavou; R Kobos; K Curran; J Ruggiero; N Zakak; R J O'Reilly; F Boulad
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.